NASDAQ:MLYS Mineralys Therapeutics (MLYS) Stock Price, News & Analysis $11.27 +0.13 (+1.17%) (As of 08/22/2024 ET) Add Compare Share Share Today's Range$10.92▼$11.3450-Day Range$9.13▼$14.5852-Week Range$5.85▼$16.91Volume145,985 shsAverage Volume184,826 shsMarket Capitalization$559.54 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Mineralys Therapeutics alerts: Email Address Mineralys Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside166.2% Upside$30.00 Price TargetShort InterestBearish7.00% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.09Based on 13 Articles This WeekInsider TradingSelling Shares$9.20 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.92) to ($3.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.91 out of 5 starsMedical Sector601st out of 923 stocksPharmaceutical Preparations Industry274th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingMineralys Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMineralys Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Mineralys Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.00% of the float of Mineralys Therapeutics has been sold short.Short Interest Ratio / Days to CoverMineralys Therapeutics has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Mineralys Therapeutics has recently decreased by 3.21%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMineralys Therapeutics does not currently pay a dividend.Dividend GrowthMineralys Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MLYS. Previous Next 1.1 News and Social Media Coverage News SentimentMineralys Therapeutics has a news sentiment score of -0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Mineralys Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for MLYS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mineralys Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,204,818.00 in company stock.Percentage Held by Insiders33.24% of the stock of Mineralys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mineralys Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($2.92) to ($3.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mineralys Therapeutics is -5.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mineralys Therapeutics is -5.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMineralys Therapeutics has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Mineralys Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad AltimetryDid Wall St. Buy Your Stocks for A Discount Last Week?New Wave of "Pre-Programmed" Stock Crashes: Like landmines, a wave of crashes just rocked the stock market... dropping one of the world's most popular stocks by 99%. It hit stocks in the energy and gold markets too. Will your favorite stock be next? This is part of a bigger stock market story... one not many on Main Street are even being told about.Click here for the details. About Mineralys Therapeutics Stock (NASDAQ:MLYS)Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Read More MLYS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MLYS Stock News HeadlinesJuly 27, 2024 | insidertrades.comInsider Selling: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Director Sells 550,000 Shares of StockAugust 18, 2024 | americanbankingnews.comMineralys Therapeutics (NASDAQ:MLYS) Earns Buy Rating from HC WainwrightAugust 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.August 17, 2024 | americanbankingnews.comQ3 2024 Earnings Forecast for Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Issued By HC WainwrightAugust 16, 2024 | uk.investing.comMineralys stock keeps Buy rating, PT at Goldman Sachs post Q2August 16, 2024 | investing.comMineralys Therapeutics kicks off key program, shares hold buy rating with StifelAugust 16, 2024 | americanbankingnews.comQ3 2024 Earnings Forecast for Mineralys Therapeutics, Inc. Issued By Lifesci Capital (NASDAQ:MLYS)August 15, 2024 | markets.businessinsider.comBuy Rating for Mineralys Therapeutics Amid Strong Financials and Promising Lorundrostat TrialsAugust 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.August 15, 2024 | msn.comMineralys Therapeutics Posts Q2 Financial Results, Updates on Clinical TrialsAugust 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Durect (DRRX) and Globus Medical (GMED)August 14, 2024 | finanznachrichten.deMineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 13, 2024 | markets.businessinsider.comMineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 13, 2024 | seekingalpha.comMineralys Therapeutics, Inc. (MLYS) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | markets.businessinsider.comMLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q2 2024August 13, 2024 | seekingalpha.comMineralys Therapeutics, Inc. 2024 Q2 - Results - Earnings Call PresentationAugust 7, 2024 | msn.comMineralys Therapeutics to Announce Q2 2024 Financial ResultsJune 14, 2024 | globenewswire.comMineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D.See More Headlines Receive MLYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today8/23/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MLYS CUSIPN/A CIK1933414 Webwww.mineralystx.com Phone888-378-6240FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Target$30.00 High Stock Price Target$30.00 Low Stock Price Target$30.00 Potential Upside/Downside+166.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,900,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.48% Return on Assets-31.10% Debt Debt-to-Equity RatioN/A Current Ratio18.06 Quick Ratio18.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.87 per share Price / Book1.92Miscellaneous Outstanding Shares49,649,000Free Float33,146,000Market Cap$559.54 million OptionableOptionable Beta1.93 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Brian Taylor Slingsby M.D. (Age 47)M.P.H., Ph.D., Founder & Executive Chairman Comp: $69.33kMr. Jon Congleton (Age 61)CEO & Director Comp: $775.77kMr. Adam Scott Levy (Age 46)CFO & Secretary Comp: $655.58kDr. David M. Rodman M.D. (Age 69)Chief Medical Officer Comp: $726.95kMs. Cindy BerejikianExecutive Vice President of OperationsMs. Sarah FosterVice President of Human ResourcesDr. Robert McKean Ph.D.Senior Vice President of CMCMs. Danielle BradburySenior Vice President of Quality AssuranceMr. Jeffrey N. FellowsSenior Vice President of Regulatory AffairsMs. Jessica IbbitsonSenior Vice President of Clinical OperationsMore ExecutivesKey CompetitorsHarmony BiosciencesNASDAQ:HRMYMirum PharmaceuticalsNASDAQ:MIRMSupernus PharmaceuticalsNASDAQ:SUPNLigand PharmaceuticalsNASDAQ:LGNDStructure TherapeuticsNASDAQ:GPCRView All CompetitorsInsiders & InstitutionsNantahala Capital Management LLCBought 200,000 shares on 8/20/2024Ownership: 1.073%Driehaus Capital Management LLCBought 74,074 shares on 8/16/2024Ownership: 0.518%Blue Owl Capital Holdings LPSold 90,741 shares on 8/15/2024Ownership: 0.907%Lion Point Capital LPBought 19,000 shares on 8/15/2024Ownership: 0.159%The Manufacturers Life Insurance Company Bought 12,432 shares on 8/15/2024Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions MLYS Stock Analysis - Frequently Asked Questions How have MLYS shares performed this year? Mineralys Therapeutics' stock was trading at $8.60 at the start of the year. Since then, MLYS shares have increased by 31.0% and is now trading at $11.27. View the best growth stocks for 2024 here. How were Mineralys Therapeutics' earnings last quarter? Mineralys Therapeutics, Inc. (NASDAQ:MLYS) issued its earnings results on Tuesday, August, 13th. The company reported ($0.83) earnings per share for the quarter, missing analysts' consensus estimates of ($0.73) by $0.10. When did Mineralys Therapeutics IPO? Mineralys Therapeutics (MLYS) raised $180 million in an IPO on Friday, February 10th 2023. The company issued 12,000,000 shares at a price of $14.00-$16.00 per share. Who are Mineralys Therapeutics' major shareholders? Mineralys Therapeutics' top institutional shareholders include Adams Street Partners LLC (3.40%), American Century Companies Inc. (1.50%), Nantahala Capital Management LLC (1.07%) and Blue Owl Capital Holdings LP (0.91%). Insiders that own company stock include Brian Taylor Slingsby, Samsara Biocapital Gp, Llc, Hbm Healthcare Investments (Ca, Ra Capital Management, LP, Jon Congleton, Adam Scott Levy and David Malcom Rodman. View institutional ownership trends. How do I buy shares of Mineralys Therapeutics? Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MLYS) was last updated on 8/23/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredDid Wall St. Buy Your Stocks for A Discount Last Week?New Wave of "Pre-Programmed" Stock Crashes: Like landmines, a wave of crashes just rocked the stock market....Altimetry | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredDaily Options Pick (Delivered)I'm going to send you my best options pick every single morning for 100% free. Why should you listen to me?...Prosper Trading Academy | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
